LX1033 FDA Approval Status
FDA Approved: No
Brand name: LX1033
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Irritable Bowel Syndrome
LX1033 is an oral tryptophan hydroxylase inhibitor in development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
Development timeline for LX1033
| Date | Article |
|---|---|
| Dec 17, 2012 | Lexicon's Drug Candidate For Irritable Bowel Syndrome (LX1033) Receives Fast Track Status From The FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
